

INDGN/SE/2024-25/56

October 28, 2024

| | |
|---|---|
| BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172 | National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN |
|---|---|

Dear Sir / Madam,

Sub: Press Release regarding financial results for the quarter ended September 30, 2024

We wish to inform you that the Company has made a press release dated October 28, 2024, announcing the financial results for the quarter ended September 30, 2024 as approved by the Board of Directors at its meeting on October 28, 2024 (VIA AUDIO/VIDEO MODE).

A copy of the Press Release is attached for your records.

Please acknowledge the receipt.

Thanking you,

Yours Sincerely,

For Indegene Limited
(Formerly known as Indegene Private Limited)

Srishti Ramesh Kaushik
Company Secretary and Compliance officer



Indegene Limited (Formerly Indegene Private Limited),
Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara,
Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: U73100KA1998PLC102040

Press release

Indegene reports 8.0% YoY growth in Revenue with a strong PAT margin of 13.4%, growing at 22.3% YoY

Bengaluru, India, October 28, 2024: Indegene, a digital-first, life sciences commercialization company, announced financial results for the quarter ended September 30, 2024.

- Achieved revenue of INR 6,868 million in Q2FY25, a growth of 8.0% YoY
- Improved PAT margin of 13.4% due to better capacity management, automation and zero debt servicing cost

| Sl. No. | Particulars | Quarter ended | | |
|---------|--|---------------|--------------|---------------|
| | | Sept 30, 2024 | Jun 30, 2024 | Sept 30, 2023 |
| 1. | Revenue from operations | 6,868 | 6,765 | 6,357 |
| 2. | Revenue from operations (\$ Mn) | 82.0 | 81.1 | 76.9 |
| 3. | YoY revenue growth from operations (%) | 8.0% | 11.4% | 17.3% |
| 4. | EBITDA | 1,267 | 1,328 | 1,224 |
| 5. | EBITDA margin (%) | 18.4% | 19.6% | 19.2% |
| 6. | Profit after tax | 917 | 877 | 750 |
| 7. | Profit margin (%) | 13.4% | 13.0% | 11.8% |

“In Q2FY25, we achieved revenue growth of 8.0% YoY. The growth is largely driven by positive momentum in both big and mid-size pharma customers. Our largest customer, which was approximately USD 42 million in revenue last year, continues to grow.” said Manish Gupta, Chairman and CEO, Indegene Limited. “Further, the revenue from our Top 5 accounts have grown 2.3% sequentially.”.

“Our earnings growth in Q2FY25 continues with EPS increasing by 13% YoY and PAT growing from INR 750 million in Q2FY24 to INR 917 million in Q2FY25. Our focus on productivity improvement through better capacity management and automation has partially offset the impact of the annual wage hike which is effective July 2024. This combined with the zero-debt servicing cost helped in improving the PAT margin to 13.4% for the quarter.” said Suhas Prabhu, CFO, Indegene Limited. “Further our return on equity post the IPO continues to be in early 20s, at a healthy 21% and return on capital employed net of cash continues to be around 48%”.



About Indegene

Indegene is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It's what drives Indegene's team and their purpose to enable healthcare organizations to be future-ready. To learn more, please visit www.indegene.com

For Investor Inquiries, please contact:
IR@Indegene.com

For media inquiries, please contact:
Yadunandan K V | yadunandan.kv@indegene.com